Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opioid analgesics

WHO retracts opioid guidance following concerns of pharmaceutical industry influence

The World Health Organization (WHO) has retracted guidance on opioid use, following concerns raised in the United States that the guidance had been influenced by opioid manufacturers.

The two pieces of guidance that have been retracted are: ‘Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicine’, first published in 2011, and ‘WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses’, published in 2012. 

In May 2019, two US politicians, Katherine Clark and Hal Rogers, published a report in which they claimed there was evidence that the two sets of guidance had been influenced by “major players in the opioid industry”. Following this report, the WHO ordered a review into the guidance.

A statement confirming the guidance retraction was published in the January 2020 issue of the Bulletin of the World Health Organization, although the statement was originally published on the WHO’s website on 20 June 2019.

In the statement, the WHO said that it takes concerns raised in 2019 “very seriously”, but said that the guidance was being discontinued “in light of new scientific evidence that has emerged since the time of their publication”. However, it added that the discontinuation would also “address any issues of conflicts of interest of the experts that have been raised”.

The statement added that WHO remains concerned about “very low access to medication for moderate and severe pain, particularly in low- and middle income countries”, but that the need for access should be balanced with awareness of the harm that can arise from misuse of pain medication.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207579

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.